SCHEDULE 13G/A: Loewenbaum Family Discloses Significant Passive Stake in CollPlant Biotechnologies

George Walter Loewenbaum and affiliated entities have filed an amended Schedule 13G/A, disclosing a combined passive beneficial ownership in CollPlant Biotechnologies Ltd., with George Walter Loewenbaum holding 9.96% of the ordinary shares.

Summary

• George Walter Loewenbaum and several affiliated trusts and partnerships (collectively, "Reporting Persons") have filed an Amendment No. 6 to Schedule 13G regarding their beneficial ownership of CollPlant Biotechnologies Ltd. ordinary shares.
• As of December 31, 2024, George Walter Loewenbaum beneficially owns 1,140,950 ordinary shares, representing 9.96% of the issuer's outstanding ordinary shares.
• This ownership for George Walter Loewenbaum includes 60,794 shares underlying American Depository Shares (ADSs) held by the Walter Loewenbaum Trust, 169,249 ordinary shares underlying ADSs held directly, and 910,907 ordinary shares underlying ADSs held in an IRA.
• Lillian S. Loewenbaum beneficially owns 89,573 ordinary shares, representing 0.78% of the class, held directly and through the Lillian Shaw Loewenbaum Trust.
• Elizabeth S. Loewenbaum beneficially owns 20,688 ordinary shares, representing 0.18% of the class.
• Other affiliated Texas-based trusts and partnerships, including Lillian S. Loewenbaum Grantor Retained Annuity Trusts I, V, and VI, The Loewenbaum 1992 Trust, The Waterproof Partnership, Ltd., The Loewenbaum Residence Trust FBO Anna Loewenbaum, and The Elizabeth Scott Loewenbaum 1992 Trust, also hold smaller percentages of the shares.
• The total number of CollPlant Biotechnologies Ltd. ordinary shares issued and outstanding as of September 30, 2024, was 11,454,512, which was used as the basis for calculating ownership percentages.
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership. It contains no positive or negative operational or financial information about the company, thus maintaining a neutral sentiment.

Positives

• Disclosure of a significant passive stake by a prominent individual and affiliated entities may signal long-term confidence in CollPlant Biotechnologies Ltd.
• The filing explicitly states the shares are not held for the purpose of changing or influencing control, indicating a passive investment approach.

Risks

• The document explicitly states that the shares are not held for the purpose of changing or influencing control, mitigating typical risks associated with large shareholder activism.
• No other risks related to the company's operations or financial health are mentioned in this ownership disclosure filing.

Future Outlook

NA

Industry Context

This filing is a standard regulatory disclosure of beneficial ownership and does not provide specific industry context or trends. It indicates continued investment interest in the biotechnology sector, specifically in CollPlant Biotechnologies Ltd.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes, which can influence market perception of stability and investor confidence.
• Management: Awareness of significant passive shareholders, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

CollPlant Biotechnologies Ltd., Schedule 13G/A, beneficial ownership, George Walter Loewenbaum, Lillian S. Loewenbaum, Elizabeth S. Loewenbaum, passive investment, SEC filing, ordinary shares, ADSs, CUSIP 19516R107